Mucosal immunization to prevent prion infection
US8685718B2 · kind B2 · utility
5Cited by
9References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2004 |
| Grant date | Apr 1, 2014 |
| Priority date | — |
| Expiry date | Jan 6, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55544
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.